Logo image of CPRX

CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

USA - NASDAQ:CPRX - US14888U1016 - Common Stock

21.405 USD
+0.39 (+1.88%)
Last: 10/21/2025, 3:48:08 PM
Fundamental Rating

8

CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make CPRX a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year CPRX was profitable.
CPRX had a positive operating cash flow in the past year.
In the past 5 years CPRX has always been profitable.
In the past 5 years CPRX always reported a positive cash flow from operatings.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

CPRX's Return On Assets of 21.47% is amongst the best of the industry. CPRX outperforms 96.82% of its industry peers.
The Return On Equity of CPRX (24.38%) is better than 96.63% of its industry peers.
With an excellent Return On Invested Capital value of 21.45%, CPRX belongs to the best of the industry, outperforming 97.75% of the companies in the same industry.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is above the industry average of 15.49%.
The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.45%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 21.47%
ROE 24.38%
ROIC 21.45%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

Looking at the Profit Margin, with a value of 37.36%, CPRX belongs to the top of the industry, outperforming 97.19% of the companies in the same industry.
CPRX's Profit Margin has been stable in the last couple of years.
CPRX has a Operating Margin of 43.58%. This is amongst the best in the industry. CPRX outperforms 99.06% of its industry peers.
CPRX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 85.78%, CPRX belongs to the best of the industry, outperforming 88.39% of the companies in the same industry.
CPRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 43.58%
PM (TTM) 37.36%
GM 85.78%
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CPRX has more shares outstanding
The number of shares outstanding for CPRX has been increased compared to 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CPRX has an Altman-Z score of 16.08. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CPRX (16.08) is better than 88.20% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.08
ROIC/WACC2.29
WACC9.37%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CPRX has a Current Ratio of 6.71. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a better Current ratio (6.71) than 67.60% of its industry peers.
CPRX has a Quick Ratio of 6.55. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a better Quick ratio (6.55) than 67.23% of its industry peers.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 6.55
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 205.56% over the past year.
CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.29% yearly.
The Revenue has grown by 28.54% in the past year. This is a very strong growth!
The Revenue has been growing by 36.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%

3.2 Future

Based on estimates for the next years, CPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.50% on average per year.
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.27% yearly.
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 12.97, which indicates a correct valuation of CPRX.
Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.19% of the companies listed in the same industry.
CPRX is valuated cheaply when we compare the Price/Earnings ratio to 27.69, which is the current average of the S&P500 Index.
CPRX is valuated correctly with a Price/Forward Earnings ratio of 12.23.
96.63% of the companies in the same industry are more expensive than CPRX, based on the Price/Forward Earnings ratio.
CPRX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.18.
Industry RankSector Rank
PE 12.97
Fwd PE 12.23
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

CPRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.94% of the companies in the same industry.
98.13% of the companies in the same industry are more expensive than CPRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.54
EV/EBITDA 6.82
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CPRX's earnings are expected to grow with 12.05% in the coming years.
PEG (NY)0.97
PEG (5Y)0.38
EPS Next 2Y15.59%
EPS Next 3Y12.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (10/21/2025, 3:48:08 PM)

21.405

+0.39 (+1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners85.12%
Inst Owner Change0.1%
Ins Owners5.59%
Ins Owner Change1.17%
Market Cap2.62B
Analysts88.57
Price Target34.68 (62.02%)
Short Float %7.56%
Short Ratio5.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)4.13%
Max EPS beat(2)29.76%
EPS beat(4)4
Avg EPS beat(4)18.54%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)15.48%
EPS beat(12)11
Avg EPS beat(12)12.83%
EPS beat(16)12
Avg EPS beat(16)7.88%
Revenue beat(2)2
Avg Revenue beat(2)3.81%
Min Revenue beat(2)2.19%
Max Revenue beat(2)5.44%
Revenue beat(4)4
Avg Revenue beat(4)3.37%
Min Revenue beat(4)2.19%
Max Revenue beat(4)5.44%
Revenue beat(8)7
Avg Revenue beat(8)2.76%
Revenue beat(12)11
Avg Revenue beat(12)3.19%
Revenue beat(16)13
Avg Revenue beat(16)2.7%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.61%
EPS NQ rev (3m)-4.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 12.97
Fwd PE 12.23
P/S 4.69
P/FCF 9.54
P/OCF 9.52
P/B 3.06
P/tB 3.65
EV/EBITDA 6.82
EPS(TTM)1.65
EY7.71%
EPS(NY)1.75
Fwd EY8.18%
FCF(TTM)2.24
FCFY10.49%
OCF(TTM)2.25
OCFY10.5%
SpS4.56
BVpS6.99
TBVpS5.87
PEG (NY)0.97
PEG (5Y)0.38
Profitability
Industry RankSector Rank
ROA 21.47%
ROE 24.38%
ROCE 28.34%
ROIC 21.45%
ROICexc 89.37%
ROICexgc 270.38%
OM 43.58%
PM (TTM) 37.36%
GM 85.78%
FCFM 49.19%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexcg growth 3Y8.72%
ROICexcg growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.99%
Cap/Sales 0.07%
Interest Coverage 165.59
Cash Conversion 97.81%
Profit Quality 131.65%
Current Ratio 6.71
Quick Ratio 6.55
Altman-Z 16.08
F-Score6
WACC9.37%
ROIC/WACC2.29
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%
EBIT growth 1Y183.49%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y121.55%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y121.67%
OCF growth 3Y58.35%
OCF growth 5Y47.28%